Do genetic susceptibility variants associate with disease severity in early active rheumatoid arthritis?

Journal of Rheumatology

Volumn 42, Issue 7, 2015, Pages 1131-1140

  Scott, Ian C ^a   Rijsdijk, Frühling ^b   Walker, Jemma ^a   Quist, Jelmar ^a   Spain, Sarah L ^a   Tan, Rachael ^a   Steer, Sophia ^a   Okada, Yukinori ^c   Raychaudhuri, Soumya ^d   Cope, Andrew P ^a   Lewis, Cathryn M ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Genetics; Hla antigens; Outcome measures; Radiography; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DRB1 ANTIGEN; ANTIRHEUMATIC AGENT;

ADULT; ALLELE; AMINO ACID ANALYSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; ARTHRITIS, RHEUMATOID; DISEASE COURSE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; THEORETICAL MODEL;

ADULT; ALLELES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX;

EID: 84940521045     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141211     Document Type: Article

References (50)

1. Knevel R, Gröndal G, Huizinga TW, Visser AW, Jónsson H, Víkingsson A, et al. Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2012;71:707-9.
2. van Steenbergen HW, Tsonaka R, Huizinga TW, le Cessie S, van der Helm-van Mil AM. Predicting the severity of joint damage in rheumatoid arthritis; the contribution of genetic factors. Ann Rheum Dis 2015;74:876-82.
3. Knevel R, de Rooy DP, Gregersen PK, Lindqvist E, Wilson AG, Grondal G, et al. Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts. Ann Rheum Dis 2012;71:1753-5.
4. Marinou I, Maxwell JR, Wilson AG. Genetic influences modulating the radiological severity of rheumatoid arthritis. Ann Rheum Dis 2010;69:476-82.
5. de Rooy DP, Zhernakova A, Tsonaka R, Willemze A, Kurreeman BA, Trynka G, et al. A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 2014;73:1163-9.
6. Knevel R, de Rooy DP, Zhernakova A, Gröndal G, Krabben A, Steinsson K, et al. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 2013;65:1684-93.
7. Krabben A, Wilson AG, de Rooy DP, Zhernakova A, Brouwer E, Lindqvist E, et al. Association of genetic variants in the IL4 and IL4R genes with the severity of joint damage in rheumatoid arthritis: a study in seven cohorts. Arthritis Rheum 2013;65:3051-7.
8. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
9. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2008;58 Suppl 2:S126-35.
10. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
11. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014;506:376-81.
12. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012;44:291-6.
13. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al; CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008;67:656-63.
14. Scott DL, Choy E. Effect of anakinra (soluble interleukin-1 receptor antagonist) as combination therapy: second UK combination therapy in early rheumatoid arthritis. King's College Lindon. [Internet. Accessed April 15, 2015.] Available from: www.isrctn.com/ISRCTN15819795?q=Effect%20of%20anakinra% 20(soluble%20interleukin-1%20receptor%20antagonist)%20as%20 combination%20therapy:%20second%20UK%20combination%20th erapy%20in%20early%20rheumatoid%20arthritis%20&filters=&so rt=&offset=1&totalResults=1&page=1&pageSize=10&searchType= basic-search
15. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013;14:661-73.
16. Jia X, Han B, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS, et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE 2013;8:e64683.
17. Brown WM, Pierce J, Hilner JE, Perdue LH, Lohman K, Li L, et al; Type 1 Diabetes Genetics Consortium. Overview of the MHC fine mapping data. Diabetes Obes Metab 2009;11 Suppl 1:2-7.
18. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013;9:e1003394.
19. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012;44:1336-40.
20. Karlson EW, Chibnik LB, Kraft P, Cui J, Keenan BT, Ding B, et al. Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. Ann Rheum Dis 2010;69:1077-85.
21. Yarwood A, Han B, Raychaudhuri S, Bowes J, Lunt M, Pappas DA, et al. A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis 2015;74:170-6.
22. Guo Y, Logan HL, Glueck DH, Muller KE. Selecting a sample size for studies with repeated measures. BMC Med Res Methodol 2013;13:100.
23. Higgins JPT, Green S; The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. [Internet. Accessed April 9, 2015.] Available from: handbook.cochrane.org/chapter-16/16-1-2-general-principles-for-dealing-with-missing- data.htm
24. Beasley TM, Erickson S, Allison DB. Rank-based inverse normal transformations are increasingly used, but are they merited? Behav Genet 2009;39:580-95.
25. Crouch DJ, Goddard GH, Lewis CM. REGENT: a risk assessment and classification algorithm for genetic and environmental factors. Eur J Hum Genet 2013;21:109-11.
26. Scott IC, Seegobin SD, Steer S, Tan R, Forabosco P, Hinks A, et al. Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. PLoS Genet 2013;9:e1003808.
27. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003;19:149-50.
28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-75.
29. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
30. Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3, 240 rheumatoid arthritis patients. Arthritis Rheum 2004;50:400-12.
31. van der Woude D, Syversen SW, van der Voort EI, Verpoort KN, Goll GL, van der Linden MP, et al. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2010;69:1110-6.
32. Mewar D, Marinou I, Coote AL, Moore DJ, Akil M, Smillie D, et al. Association between radiographic severity of rheumatoid arthritis and shared epitope alleles: differing mechanisms of susceptibility and protection. Ann Rheum Dis 2008;67:980-3.
33. Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, et al. OP0190 Personalized genetic medicine: amino acid positions 11, 71 and 74 in HLA-DRB1 predict disease severity, treatment response and mortality in rheumatoid arthritis; multi-centre prospective cohort studies. Ann Rheum Dis 2014;73 Suppl 2:134.
34. Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, et al. Abstract session: emerging concepts in genomics and genetics-personalized genetic medicine: amino acid positions 11, 71 and 74 in HLA-DRB1 predict disease severity, treatment response and mortality in rheumatoid arthritis. EULAR 2014 Congress Presentations [Internet. Accessed April 9, 2015.] Available from: www.pathlms.com/eular/events/147/thumbnail-video- presentations/2538
35. Scott IC, Steer S, Lewis CM, Cope AP. Precipitating and perpetuating factors of rheumatoid arthritis immunopathology: linking the triad of genetic predisposition, environmental risk factors and autoimmunity to disease pathogenesis. Best Pract Res Clin Rheumatol 2011;25:447-68.
36. Seegobin SD, Ma MH, Dahanayake C, Cope AP, Scott DL, Lewis CM, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther 2014;16:R13.
37. Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP. The protective effect of alcohol on developing rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology 2013; 52:856-67.
38. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006;8:R133.
39. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008;14:575-81.
40. Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011;63:645-53.
41. Knevel R, Klein K, Somers K, Ospelt C, Houwing-Duistermaat JJ, van Nies JA, et al. Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Ann Rheum Dis 2014;73:2038-46.
42. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M; Guideline Development Group. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009;338:b702.
43. Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I, et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 2007;26:1111-8.
44. Jansen LM, van Schaardenburg D, van Der Horst-Bruinsma IE, Bezemer PD, Dijkmans BA. Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis 2000;59:223-6.
45. Combe B, Cantagrel A, Goupille P, Bozonnat MC, Sibilia J, Eliaou JF, et al. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol 2003;30:2344-9.
46. Wiles NJ, Dunn G, Barrett EM, Harrison BJ, Silman AJ, Symmons DP. One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. J Rheumatol 2000;27:2360-6.
47. Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2013;72:858-62.
48. Viatte S, Plant D, Lunt M, Fu B, Flynn E, Parker BJ, et al. Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study further replicates the TRAF1 association with radiological damage. J Rheumatol 2013;40:144-56.
49. Teare MD, Knevel R, Morgan MD, Kleszcz A, Emery P, Moore DJ, et al. Allele-dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis. Arthritis Rheum 2013;65:2555-61.
50. Han B, Diogo D, Eyre S, Kallberg H, Zhernakova A, Bowes J, et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet 2014;94:522-32.